• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Leonard John M was granted 1,592 shares, increasing direct ownership by 12% to 15,375 units (SEC Form 4)

    4/25/25 6:17:57 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LEONARD JOHN M

    (Last) (First) (Middle)
    C/O IQVIA HOLDINGS INC.
    2400 ELLIS ROAD

    (Street)
    DURHAM NC 27703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IQVIA HOLDINGS INC. [ IQV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/24/2025 A 1,592(1) A $0 15,375 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant.
    Remarks:
    /s/ Matthew Gilmartin, Attorney-in-Fact for John M. Leonard 04/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IQV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    10/14/2024Buy
    Redburn Atlantic
    9/4/2024$275.00Outperform
    RBC Capital Mkts
    7/24/2024$266.00 → $242.00Buy → Hold
    Jefferies
    6/6/2024$270.00Buy
    Goldman
    More analyst ratings

    $IQV
    SEC Filings

    See more
    • IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      6/4/25 4:30:40 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 8-K filed by IQVIA Holdings Inc.

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      6/2/25 5:22:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by IQVIA Holdings Inc.

      SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      5/9/25 11:41:43 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wims Morris Leslie

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:51:44 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Goggins Colleen A

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:51:17 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Fasano Jim

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:50:50 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers

      Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 17, 2025 /PRNewswire/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB:AVAI), IQVIA Holdings Inc. (NYSE:IQV), S

      6/17/25 10:17:00 AM ET
      $CI
      $IQV
      $RDNT
      $SOUN
      Medical Specialities
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Computer Software: Prepackaged Software
    • IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement'

      IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program. IQVIA's breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that helps patients and their caregivers participate in decentralized clinical trials around the world. The platform is configurable, multilingual and compatible with web, iOS and Android and is available across many geographic regions, increasing p

      6/16/25 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Launches New AI Agents for Life Sciences and Healthcare

      IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA's new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transforming business processes and patient outcomes. "This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry backed by deep industry expertise and powerful technology partnersh

      6/11/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IQVIA downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

      4/25/25 8:30:17 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by Barclays with a new price target

      Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

      4/10/25 8:49:29 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by BTIG Research

      BTIG Research downgraded IQVIA from Buy to Neutral

      2/3/25 8:45:01 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      2/7/25 7:03:59 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Leadership Updates

    Live Leadership Updates

    See more
    • IQVIA Appoints Richard Staub III President of Research & Development Solutions

      IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

      9/25/23 8:01:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

      IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

      6/7/22 8:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

      3/14/22 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      8/15/24 7:57:23 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by IQVIA Holdings Inc.

      SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

      2/14/24 4:11:54 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

      SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      1/25/24 4:59:33 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Financials

    Live finance-specific insights

    See more
    • IQVIA Reports First-Quarter 2025 Results

      Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS Revenue of $1,546 million, up 6.4 percent reported year-over-year and 7.6 percent at constant currency Operating Cash Flow of $568 million and Free Cash Flow of $426 million, up 13 percent year-over-year, representing 89 percent of Adjusted Net Income Rep

      5/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

      IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive

      4/21/25 4:15:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

      Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

      2/6/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care